US Patent

US11234939 — Dosage forms comprising a plasma kallikrein inhibitor

Method of Use · Assigned to Kalvista Pharmaceuticals Ltd · Expires 2039-01-26 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects oral solid dosage forms of a plasma kallikrein inhibitor, specifically a compound of Formula A in a solid form called Form 1.

USPTO Abstract

The present invention relates to oral solid dosage forms comprising a plasma kallikrein inhibitor, in particular a solid form (Form 1) of the compound of Formula A. Also provided are methods of preparing oral solid dosage forms comprising the compound of Formula A using Form 1 of the compound of Formula A.

Drugs covered by this patent

Ekterly (SEBETRALSTAT) · Kalvista

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4223`	—	Ekterly

Patent Metadata

Patent number: US11234939
Jurisdiction: US
Classification: Method of Use
Expires: 2039-01-26
Drug substance claim: No
Drug product claim: Yes
Assignee: Kalvista Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.